Radiotherapy to Treat Spreading Spots in Metastatic Melanoma
Tests focused radiation on a few progressing melanoma spots in adults.
Plain-language title generated from the registry record
Registry title: Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- University Health NetworkToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT07112170
- Record updated
- 5 March 2026
- Original description
This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.Read full original descriptionShow less
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma (CURB-Melanoma) - a Phase 2 Clinical Trial
This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.
Inclusion: Age 18 or older; ECOG 0-2; Willing and able to provide informed consent; Metastatic melanoma detected on imaging and clinically confirmed; Treated with first line immunotherapy or BRAF inhibitors; No upper limit to the number of total metastatic sites, but a maximum of ten progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extra cranial; Patients who had any prior radiation therapy near or overlapping with the oligoprogressive sites are allowed to enroll; All sites of oligoprogression that can be safely treated with SBRT or hypofractionated radiotherapy.
Exclusion: Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia or scleroderma; Prior radiotherapy near the oligoprogressive lesion precluding SBRT or hypofractionated radiotherapy due to exceeding OAR tolerance; >10 extracranial sites of progressive disease; Leptomeningeal disease; Any other condition which in the judgment of the investigator would make the patient inappropriate for entry into this study; Pregnancy; Any psychological, sociological or geographical issue potentially hampering compliance with the study.